Tenaya Therapeutics, Inc. (TNYA) Reports Q4 EPS of (12c), In Line with Consensus
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) reported Q4 EPS of (12c), matching the consensus estimate. CEO Faraz Ali highlighted clinical progress in 2025 and anticipates further updates in the first half of 2026 for its gene therapy programs TN-201 and TN-401. The company also presented positive preclinical data for its HDAC6 inhibitor, TN-301, showing improvements in Duchenne muscular dystrophy models.
How this was made

The 30-second read
Why it matters
The positive clinical data and earnings alignment suggest a stable outlook, but the biotech sector's volatility warrants caution.
Market read
The company's clinical progress and earnings report are relevant for biotech investors, with potential sector-wide implications.
What to watch
Regulatory hurdles or clinical trial failures could negatively impact stock; broader market conditions may influence biotech sector performance.
Background
Tenaya Therapeutics is advancing gene therapy programs and HDAC6 inhibitors, with recent clinical updates and earnings reports.
Ticker impact
The news reports quarterly earnings and clinical progress, indicating ongoing development and potential future catalysts.
Limited immediate price movement; potential for upward movement if clinical progress translates into valuation uplift.
Earnings in line with consensus suggest no immediate surprise; clinical progress is positive but may not be fully priced in yet.
Market effects
Potential positive impact on biotech and gene therapy sectors
Limited regional impact, primarily affecting US biotech stocks
Moderate, as biotech developments can influence global health markets
Counterpoint
Clinical progress may be already priced in; any delays or setbacks could lead to downside risk.
Key entities
- CompanyTenaya Therapeutics, Inc.
A biotech firm focused on gene therapy and neurodegenerative disease treatments.
- ProductTN-201
A gene therapy program in clinical development.
- ProductTN-401
Another gene therapy candidate in early stages.
- CompoundTN-301
An HDAC6 inhibitor showing promise in preclinical models.

